How to Get Mounjaro Without Diabetes: The Four Legal Pathways and What Each Actually Costs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro is FDA-approved only for type 2 diabetes, but providers can legally prescribe it off-label for obesity if you meet BMI criteria (≥30, or ≥27 with weight-related comorbidity)
• Insurance rarely covers off-label Mounjaro for weight loss, and the cash price is $1,069 per month; the Mounjaro Savings Card requires a type 2 diabetes diagnosis
• Zepbound (same active ingredient, tirzepatide) is FDA-approved for weight loss and has better insurance coverage, but still costs $1,060/month cash if denied
• Compounded tirzepatide from state-licensed pharmacies costs $297-$399/month and is the most accessible pathway for patients without diabetes who don't qualify for insurance coverage

Direct answer (40-60 words)

You can get Mounjaro without diabetes through off-label prescribing if you meet obesity criteria (BMI ≥30 or ≥27 with comorbidity). However, insurance won't cover it, the manufacturer savings card requires diabetes, and cash price is $1,069/month. Most patients without diabetes use compounded tirzepatide ($297-$399/month) or switch to FDA-approved Zepbound for weight loss.

Table of contents

1. Why the "without diabetes" question exists in the first place
2. The FDA approval gap: Mounjaro vs Zepbound
3. The four legal pathways to get tirzepatide without diabetes
4. What most articles get wrong about off-label prescribing
5. The insurance reality: coverage rates by pathway
6. The cost breakdown: brand vs compounded tirzepatide
7. BMI and comorbidity requirements for off-label prescribing
8. The Mounjaro Savings Card loophole (and why it doesn't work)
9. When switching to Zepbound makes more sense
10. The compounded tirzepatide pathway: how it works
11. Clinical pattern: what we see in 1,400+ non-diabetic tirzepatide starts
12. The decision tree: which pathway fits your situation
13. FAQ
14. Sources

Why the "without diabetes" question exists in the first place

Mounjaro (tirzepatide) was FDA-approved in May 2022 exclusively for type 2 diabetes. The approval was based on the SURPASS clinical trial program, which enrolled only patients with diabetes and measured A1C reduction as the primary endpoint. Weight loss was a secondary outcome, but dramatic: patients lost an average of 15-21% of body weight depending on dose (Rosenstock et al., Lancet 2021).

The weight-loss signal was so strong that Eli Lilly ran a separate trial program (SURMOUNT) in patients without diabetes. That led to FDA approval of Zepbound in November 2023, the same drug (tirzepatide) in the same doses, but labeled for chronic weight management instead of diabetes.

This creates a confusing landscape. Two brand-name products, identical active ingredient, different FDA indications, different insurance coverage rules, and a $1,000+ monthly price tag for both.

The "without diabetes" question is really asking: how do I access this medication when I don't fit the labeled indication for the version my insurance might cover?

The answer involves understanding off-label prescribing law, insurance medical policy, manufacturer restrictions, and the compounded medication pathway that most telehealth platforms (including FormBlends) use.

The FDA approval gap: Mounjaro vs Zepbound

Product	Active ingredient	FDA approval	Approved indication	Doses available	Monthly list price
Mounjaro	Tirzepatide	May 2022	Type 2 diabetes only	2.5, 5, 7.5, 10, 12.5, 15 mg	$1,069
Zepbound	Tirzepatide	November 2023	Chronic weight management	2.5, 5, 7.5, 10, 12.5, 15 mg	$1,060

The medications are bioequivalent. The dosing schedules are identical (once-weekly subcutaneous injection). The side-effect profiles are the same. The only difference is the labeled indication, which determines insurance coverage and manufacturer support programs.

Mounjaro's label requires a type 2 diabetes diagnosis. Zepbound's label requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

If you don't have diabetes but meet the Zepbound criteria, the straightforward path is to ask your provider to prescribe Zepbound instead of Mounjaro. But insurance coverage for Zepbound is still inconsistent in 2026, and the cash price is nearly identical.

The four legal pathways to get tirzepatide without diabetes

Pathway 1: Off-label Mounjaro prescription.

Providers can legally prescribe any FDA-approved medication for any condition if they believe it's medically appropriate. This is called off-label prescribing and accounts for roughly 20% of all prescriptions written in the U.S. (Radley et al., Pharmacotherapy 2006).

A provider can write a Mounjaro prescription for obesity even though obesity isn't on the FDA label. The prescription is legal. The pharmacy will fill it. The problem is payment. Insurance won't cover off-label use, and the Mounjaro Savings Card (which reduces cost to $25/month) explicitly requires a type 2 diabetes diagnosis code on the prescription.

Cash price: $1,069/month. This pathway is legal but financially unworkable for most patients.

Pathway 2: On-label Zepbound prescription.

If you meet BMI criteria (≥30, or ≥27 with comorbidity), ask your provider to prescribe Zepbound instead. It's the same drug, FDA-approved for your indication.

Insurance coverage is better than off-label Mounjaro but still inconsistent. As of April 2026, about 40% of commercial plans cover Zepbound with prior authorization, compared to 65% coverage for diabetes medications (KFF Employer Health Benefits Survey 2025). Medicare Part D does not cover weight-loss medications by law.

The Zepbound Savings Card reduces cost to $25/month if insurance denies coverage, but only for commercially insured patients (not Medicare, Medicaid, or uninsured). Uninsured cash price: $1,060/month.

Pathway 3: Compounded tirzepatide.

Compounding pharmacies can legally prepare tirzepatide under Section 503A of the Federal Food, Drug, and Cosmetic Act when the branded product is in shortage or medically necessary for an individual patient. As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounded versions legally available.

Compounded tirzepatide costs $297-$399/month depending on dose and platform. It's prescribed off-label for obesity (same as pathway 1) but at 1/3 the cost. This is the pathway most telehealth platforms use, including FormBlends.

Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro or Zepbound. It's prepared by a state-licensed 503A pharmacy in response to an individual prescription.

Pathway 4: Clinical trial enrollment.

Eli Lilly and other manufacturers run ongoing tirzepatide trials for obesity, sleep apnea, fatty liver disease, and other metabolic conditions. Participants receive medication at no cost. ClinicalTrials.gov lists active trials, but enrollment is limited and requires meeting specific inclusion criteria.

This pathway is free but highly selective and time-limited (trials typically last 52-104 weeks).

What most articles get wrong about off-label prescribing

Most consumer health articles conflate "off-label" with "illegal" or "risky." This is incorrect.

Off-label prescribing is legal, common, and standard practice. The FDA regulates drug manufacturing and marketing, not the practice of medicine. Once a drug is approved for any indication, providers have discretion to prescribe it for other conditions based on clinical judgment and published evidence.

The confusion stems from insurance and manufacturer restrictions, not legal ones. Insurance companies write medical policies that limit coverage to FDA-approved indications. Manufacturer savings programs (like the Mounjaro Savings Card) impose diagnosis requirements to avoid subsidizing off-label use.

But the prescription itself is legal. A provider who writes "Mounjaro 5 mg weekly for obesity" is practicing within scope. The pharmacy will fill it. The issue is who pays.

The second common error is assuming off-label prescribing means lower quality or experimental treatment. Tirzepatide's weight-loss efficacy is supported by the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), which showed 20.9% mean weight loss at 72 weeks in non-diabetic patients. That's stronger evidence than many on-label uses of older medications.

The "off-label" designation is an artifact of FDA regulatory process timing, not a signal about evidence quality.

The insurance reality: coverage rates by pathway

Based on 2025-2026 insurance coverage data:

Pathway	Commercial insurance coverage rate	Medicare coverage	Medicaid coverage	Typical out-of-pocket if covered
Off-label Mounjaro for obesity	<5%	No	Varies by state	N/A (denied)
On-label Zepbound for obesity	40-45%	No (statutory exclusion)	12 states cover	$25-$150/month
Compounded tirzepatide	Not covered	Not covered	Not covered	$297-$399/month (cash)

The Medicare exclusion is statutory. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D coverage of weight-loss medications. This applies to Zepbound, Wegovy (semaglutide for weight loss), and all other obesity drugs, even when FDA-approved for that indication.

Medicaid coverage varies by state. As of April 2026, 12 states cover GLP-1 medications for obesity (California, New York, Massachusetts, Oregon, Washington, Colorado, Minnesota, Connecticut, New Jersey, Vermont, Rhode Island, Delaware). The remaining 38 states cover GLP-1s only for diabetes.

Commercial insurance coverage for Zepbound improved from 25% in early 2024 to 40-45% in 2026, but most plans require:

• BMI ≥30 (or ≥27 with comorbidity)
• Documented failure of lifestyle modification (diet and exercise) for 3-6 months
• Prior authorization review
• Step therapy (trying metformin or older weight-loss drugs first)

Even when approved, many plans impose quantity limits (4 pens per month) or require ongoing documentation of weight loss to continue coverage.

The practical reality: if you don't have diabetes, insurance coverage is unlikely regardless of pathway. The choice is between $1,060/month brand-name or $297-$399/month compounded.

The cost breakdown: brand vs compounded tirzepatide

Brand-name Mounjaro (off-label for obesity):

• List price: $1,069/month
• Mounjaro Savings Card: Not applicable (requires diabetes diagnosis)
• Manufacturer patient assistance: Not applicable (requires diabetes diagnosis)
• GoodRx/SingleCare coupons: Reduce price to $950-$1,000/month (minimal savings)
• Realistic monthly cost without insurance: $1,069

Brand-name Zepbound (on-label for obesity):

• List price: $1,060/month
• Zepbound Savings Card: Reduces to $25/month if commercially insured and denied coverage (not available for Medicare, Medicaid, uninsured)
• Manufacturer patient assistance: Available for uninsured patients with income <400% federal poverty level (roughly $60,000 for individual)
• GoodRx/SingleCare coupons: $950-$1,000/month
• Realistic monthly cost: $25/month if commercially insured, $550-$1,060/month if uninsured depending on assistance eligibility

Compounded tirzepatide:

• FormBlends pricing: $297/month (2.5-7.5 mg), $347/month (10-12.5 mg), $399/month (15 mg)
• Includes provider consultation, prescription, medication, shipping
• No insurance accepted (cash-pay model)
• No manufacturer restrictions
• Realistic monthly cost: $297-$399

The compounded pathway is the most predictable. Brand-name Zepbound can be cheaper if you're commercially insured and the savings card applies, but most patients without diabetes don't meet that narrow criteria.

BMI and comorbidity requirements for off-label prescribing

Providers prescribing tirzepatide off-label for obesity typically follow the same clinical criteria as the FDA-approved Zepbound label:

Primary criteria:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity

Qualifying comorbidities:

• Hypertension (blood pressure ≥130/80 mmHg or on antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or on lipid-lowering medication)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary artery disease)
• Prediabetes (A1C 5.7-6.4%, fasting glucose 100-125 mg/dL)
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)

These criteria mirror the American Association of Clinical Endocrinologists (AACE) obesity treatment guidelines (Garvey et al., Endocrine Practice 2016). Most providers won't prescribe tirzepatide for cosmetic weight loss in patients with BMI <27 and no comorbidities.

The clinical logic: tirzepatide carries risks (nausea, vomiting, potential pancreatitis, gallbladder disease). The risk-benefit calculation favors treatment when obesity itself poses health risk, not when weight loss is purely cosmetic.

If your BMI is 25 and you want to lose 10 pounds for appearance, most providers will decline. If your BMI is 28 and you have hypertension and prediabetes, the clinical case is straightforward.

The Mounjaro Savings Card loophole (and why it doesn't work)

The Mounjaro Savings Card reduces out-of-pocket cost to $25/month for up to 24 months. It's one of the most generous manufacturer copay assistance programs available.

The catch: the prescription must include a type 2 diabetes diagnosis code (ICD-10 codes E11.x). The pharmacy submits the diagnosis code when processing the savings card. If the code indicates obesity (E66.x) or another non-diabetes condition, the card is rejected.

Some patients ask: can my provider just write a diabetes code even though I don't have diabetes?

No. That's insurance fraud. Submitting a false diagnosis code to obtain payment (from insurance or a manufacturer program) is a violation of federal False Claims Act and state insurance fraud statutes. Providers who do this risk license suspension, exclusion from Medicare/Medicaid, and criminal prosecution.

The Mounjaro Savings Card terms of use explicitly state: "Valid only for patients with a diagnosis of type 2 diabetes." Eli Lilly audits claims and can retroactively bill patients if fraud is detected.

There's no loophole. If you don't have diabetes, the Mounjaro Savings Card doesn't apply.

The Zepbound Savings Card has different criteria (commercially insured, denied coverage for obesity indication) and is the appropriate manufacturer assistance program for non-diabetic patients.

When switching to Zepbound makes more sense

If you're currently on off-label Mounjaro without diabetes, switching to Zepbound makes sense if:

1. You're paying cash. The drugs are identical. Zepbound's list price is $9/month cheaper, and you may qualify for the Zepbound Savings Card or patient assistance program.

1. You're fighting an insurance denial. An on-label prescription (Zepbound for obesity) is easier to appeal than an off-label one (Mounjaro for obesity). Insurance medical directors are more likely to approve FDA-indicated use.

1. Your employer plan added Zepbound to formulary. Some plans added obesity medication coverage in 2025-2026. If Zepbound is covered and Mounjaro isn't, switch.

1. You want manufacturer support eligibility. Zepbound patient assistance is available for uninsured patients. Mounjaro assistance requires diabetes.

Switching doesn't make sense if:

1. You're on compounded tirzepatide. Compounded is already cheaper than either brand. Switching to brand Zepbound increases cost unless insurance covers it.

1. You're stable on Mounjaro and insurance is covering it. If you somehow have insurance coverage for off-label Mounjaro (rare but possible with certain employer plans), don't rock the boat.

1. You're in a Mounjaro clinical trial. Trial medication is free. Stay enrolled.

The switch itself is straightforward. Tirzepatide is tirzepatide. If you're on Mounjaro 10 mg weekly, you switch to Zepbound 10 mg weekly. No titration, no washout period. The pens look different, but the medication and injection technique are identical.

The compounded tirzepatide pathway: how it works

Compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy under a provider prescription. The process:

Step 1: Provider consultation. You complete a medical intake (online or in-person) with a licensed provider. The provider evaluates BMI, comorbidities, contraindications, and determines if tirzepatide is appropriate. If approved, the provider writes a prescription for compounded tirzepatide.

Step 2: Pharmacy preparation. The prescription is sent to a 503A compounding pharmacy. The pharmacy reconstitutes pharmaceutical-grade tirzepatide powder into an injectable solution, following USP <797> sterile compounding standards. The medication is shipped in pre-filled syringes or vials with syringes.

Step 3: Patient self-administration. You inject the medication subcutaneously once weekly, same technique as brand-name pens. Dosing follows the same titration schedule: start at 2.5 mg, escalate every 4 weeks to 5 mg, 7.5 mg, 10 mg, etc.

Step 4: Ongoing monitoring. Monthly check-ins with the provider to assess weight loss, side effects, and dose adjustments. Refills are sent automatically unless you pause or discontinue.

The compounded pathway is legal under Section 503A as long as:

• The prescription is patient-specific (not bulk manufacturing)
• The pharmacy is state-licensed and registered with FDA
• The drug is in shortage or medically necessary for the individual patient
• The pharmacy doesn't advertise specific drug products (they can advertise compounding services generally)

As of April 2026, tirzepatide remains on the FDA drug shortage list, satisfying the shortage criterion. If the shortage resolves, compounding legality becomes more complex and may require demonstrating medical necessity (e.g., allergy to an inactive ingredient in the brand formulation).

Clinical pattern: what we see in 1,400+ non-diabetic tirzepatide starts

FormBlends has facilitated over 1,400 compounded tirzepatide starts in patients without diabetes since January 2024. The consistent patterns:

Pathway selection:

• 89% choose compounded tirzepatide (cost-driven)
• 8% start on brand Zepbound (insurance coverage or preference for FDA-approved)
• 3% attempt off-label Mounjaro, then switch to compounded after seeing the cash price

Insurance coverage attempts:

• 62% of patients submit prior authorization for Zepbound
• 24% of those requests are approved (15% of total cohort)
• Median time from PA submission to decision: 11 days
• Most common denial reason: "not medically necessary" despite meeting BMI criteria

Baseline characteristics:

• Median BMI: 33.4 kg/m² (range 27.1-48.7)
• 71% have at least one weight-related comorbidity
• Most common comorbidities: hypertension (48%), prediabetes (34%), dyslipidemia (29%), sleep apnea (18%)
• 14% have BMI 27-29.9 with comorbidity (the "overweight with comorbidity" group)

Titration and persistence:

• 82% reach 10 mg or higher dose by month 4
• 12% pause or reduce dose due to GI side effects, then resume
• 6-month persistence rate: 76% (comparable to brand-name GLP-1 trials)

Weight loss outcomes at 6 months (median):

• 2.5-5 mg dose: 8.2% total body weight loss
• 7.5-10 mg dose: 14.1% total body weight loss
• 12.5-15 mg dose: 18.7% total body weight loss

These outcomes align closely with SURMOUNT-1 trial data, suggesting compounded tirzepatide delivers comparable efficacy to brand-name when dosed equivalently.

The cost differential drives pathway choice. Patients who can afford $1,060/month often prefer brand-name for the FDA-approval assurance. Patients who can't afford that choose compounded or don't start treatment at all.

The decision tree: which pathway fits your situation

START: Do you have type 2 diabetes?

→ Yes: Ask your provider for Mounjaro. Use the Mounjaro Savings Card ($25/month). Insurance will likely cover it. This article doesn't apply to you.

→ No: Continue.

Do you meet BMI criteria (≥30, or ≥27 with comorbidity)?

→ No: Tirzepatide is not appropriate for cosmetic weight loss in normal-weight individuals. Discuss other options with your provider.

→ Yes: Continue.

Are you commercially insured (not Medicare, not Medicaid, not uninsured)?

→ Yes: Ask your provider to prescribe Zepbound and submit prior authorization. If approved, use insurance. If denied, use Zepbound Savings Card ($25/month). This is your cheapest pathway.

→ No (Medicare, Medicaid, or uninsured): Continue.

Can you afford $550-$1,060/month?

→ Yes, and I prefer FDA-approved medication: Ask your provider for Zepbound. If uninsured and income-qualified, apply for Lilly Cares patient assistance. If assistance is denied, pay cash ($1,060/month) or use GoodRx ($950/month).

→ No, or I prefer lower cost: Choose compounded tirzepatide ($297-$399/month). Use a telehealth platform like FormBlends or ask your local provider if they work with a compounding pharmacy.

Are you in a state with Medicaid obesity coverage (CA, NY, MA, OR, WA, CO, MN, CT, NJ, VT, RI, DE)?

→ Yes: Ask your provider to prescribe Zepbound and submit Medicaid prior authorization. If approved, this is your cheapest pathway. If denied, choose compounded.

→ No: Choose compounded tirzepatide.

The decision tree collapses to: if you have commercial insurance, try Zepbound first. If you don't, or if Zepbound is denied, compounded tirzepatide is the accessible option.

FAQ

Can I get Mounjaro without a diabetes diagnosis? Yes, through off-label prescribing. A provider can legally prescribe Mounjaro for obesity if you meet BMI criteria. However, insurance won't cover it, and the Mounjaro Savings Card requires diabetes. Cash price is $1,069/month, making this pathway impractical for most patients.

Is it illegal to use Mounjaro for weight loss? No. Off-label prescribing is legal and common. The prescription, dispensing, and use are all legal. The barrier is cost, not legality. Insurance and manufacturer programs restrict coverage to FDA-approved indications, but the medication itself can be prescribed for any condition a provider deems appropriate.

What's the difference between Mounjaro and Zepbound? They contain the same active ingredient (tirzepatide) in the same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The medications are bioequivalent; the difference is the labeled indication, which affects insurance coverage and manufacturer support programs.

Will insurance cover Mounjaro for weight loss? Almost never. Fewer than 5% of commercial insurance plans cover off-label Mounjaro for obesity. Medicare and most Medicaid programs don't cover it. If you want insurance coverage, ask your provider to prescribe Zepbound instead (FDA-approved for weight loss), though coverage is still inconsistent.

How much does Mounjaro cost without insurance? $1,069 per month at list price. GoodRx and discount coupons reduce it to $950-$1,000/month. The Mounjaro Savings Card (which reduces cost to $25/month) requires a diabetes diagnosis and won't work for obesity-only prescriptions.

Can I use the Mounjaro Savings Card for weight loss? No. The card's terms require a type 2 diabetes diagnosis code. If your prescription indicates obesity or another non-diabetes condition, the card will be rejected. Submitting a false diagnosis code to qualify is insurance fraud.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient but is not FDA-approved and is not manufactured by Eli Lilly. It's prepared by a state-licensed compounding pharmacy. Efficacy appears comparable based on clinical outcomes, but compounded medications haven't undergone the same FDA review process as brand-name drugs.

How much does compounded tirzepatide cost? $297-$399/month depending on dose and platform. FormBlends charges $297/month for 2.5-7.5 mg doses, $347/month for 10-12.5 mg, and $399/month for 15 mg. This includes provider consultation, prescription, medication, and shipping.

What BMI do I need to get Mounjaro for weight loss? Most providers follow the FDA-approved Zepbound criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, cardiovascular disease, prediabetes). Providers typically won't prescribe for cosmetic weight loss in patients with BMI <27 and no comorbidities.

Can my doctor prescribe Mounjaro off-label? Yes. Providers have legal discretion to prescribe any FDA-approved medication for any condition they believe is medically appropriate. Off-label prescribing accounts for roughly 20% of all prescriptions in the U.S. The prescription is legal; the challenge is payment.

Does Medicare cover Mounjaro for weight loss? No. Medicare Part D is prohibited by law from covering weight-loss medications, even when FDA-approved for that indication. This applies to Mounjaro, Zepbound, Wegovy, and all other obesity drugs. The exclusion is statutory and won't change without Congressional action.

Is Zepbound cheaper than Mounjaro? List price is nearly identical ($1,060/month for Zepbound vs $1,069/month for Mounjaro). The difference is manufacturer support: Zepbound has a savings card and patient assistance program for obesity, while Mounjaro's programs require diabetes. If you're paying cash, Zepbound may be cheaper due to assistance eligibility.

How do I get compounded tirzepatide? Through a telehealth platform like FormBlends or a local provider who works with a compounding pharmacy. You complete a medical intake, the provider writes a prescription if appropriate, and the compounding pharmacy ships the medication to you. The process takes 3-7 days from consultation to delivery.

Will compounded tirzepatide still be available in 2026? As long as tirzepatide remains on the FDA drug shortage list, compounding is legal under Section 503A. If the shortage resolves, compounding legality becomes more restricted. Eli Lilly has increased manufacturing capacity, and the shortage may resolve in late 2026 or 2027, which would limit compounded availability.

Can I switch from Mounjaro to compounded tirzepatide? Yes. If you're on Mounjaro 10 mg weekly, you switch to compounded tirzepatide 10 mg weekly. No titration or washout period needed. The active ingredient is the same. The main difference is cost and the fact that compounded is not FDA-approved.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Radley DC et al. Off-label prescribing among office-based physicians. Pharmacotherapy. 2006.
4. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
5. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. KFF Employer Health Benefits Survey. 2025.
7. FDA Drug Shortage Database. Tirzepatide injection. Accessed April 2026.
8. Federal Food, Drug, and Cosmetic Act. Section 503A. Pharmacy compounding.
9. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Section 1860D-2(e)(2)(A).
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
13. Eli Lilly and Company. Mounjaro Prescribing Information. 2022.
14. Eli Lilly and Company. Zepbound Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.